The Japanese encephalitis virus (JEV), which belongs to the genus *Flavivirus* of the family Flaviviridae, causes viral encephalitis, in the Asia-Pacific region.[@cit0001] Approximately 50,000 cases of viral encephalitis are reported every year, of which 10,000 result in death, of those who recover, up to 15,000 are left with severe complications such as permanent brain damage.[@cit0003] Three types of Japanese encephalitis (JE) vaccines for human use are currently in use: a mouse brain-derived and inactivated vaccine, a cell culture-derived inactivated vaccine, and a cell culture-derived live attenuated JE vaccine.[@cit0002] The mouse brain-derived inactivated JE vaccine is produced in several Asian countries, and also widely used within the Korean JE control program.[@cit0002] In 2013, the Korean Ministry of Food and Drug Safety (MFDS) commissioned the production of the 3^rd^ national standard candidate material to a Korean JE vaccine manufacturer in order to replace the 2^nd^ national standard to encourage national lot-release potency testing of the Nakayama-NIH strain--derived JE vaccine. The manufacturing method used in this exercise was same as that used during establishment of the 1^st^ and the 2^nd^ national standard material.[@cit0005] Following the manufacturing process, 3 thousand lyophilized vials were delivered to MFDS and some of them were used to qualify the material. The quality control (QC) items were selected on the basis of the testing criteria for the JE vaccine per the Minimum Requirements for Biological Products (MBP) of Korea as well as the World Health Organization requirements for JE vaccines (inactivated) for human use.[@cit0002] Although the potency testing was performed in accordance with the test method in the MBP, other assays except potency testing were accomplished by Korean Pharmacopoeia (KP).[@cit0007]

[Table 1](#t0001){ref-type="table"} shows the results of QC assessment during the manufacture of the candidate material. As shown, residual protein was detected at a concentration of 37.8 μg/mL in the final product, which was lower than the minimum criterion (80 μg/mL). The pH was 7.2 and moisture content was 0.8%, which fulfilled the specifications of the JE vaccine standard. In terms of sterility testing, no bacterial or fungal growth was observed in the final product, confirming that the candidate material was manufactured under sterile conditions. In addition, Foreign Insoluble Matter Test and Insoluble Particulate Matter Test for Injections satisfied to the respective specifications. Using storage conditions identical to those used for JE vaccine standard material, testing at −70 ± 10°C for up to 24 months resulted in no major changes in the potency of the candidate material. Additionally, the moisture content of the candidate material was similar to that of the 2^nd^ standard material. (data not shown) The long-term stability of the standard material will continue to be monitored under the assurance program for national standards by MFDS. Table 1.QC test results for the 3rd national JE vaccine standard candidate material.TestSource of Test MethodSpecificationTest resultProtein content[^a^](#t1fn0001){ref-type="fn"} (μg/mL)KP-07-35≤ 8037.8pH [^b^](#t1fn0002){ref-type="fn"}KP-07-416.8 -- 7.47.2Moisture content[^c^](#t1fn0003){ref-type="fn"} (%)KP-07-29≤ 3.00.8Sterility [^d^](#t1fn0004){ref-type="fn"}KP-07-47No growthNo growthForeign insoluble matter[^e^](#t1fn0005){ref-type="fn"}KP-07-21NoneNoneInsoluble particulate matter for injection[^f^](#t1fn0006){ref-type="fn"} (particles/vial)KP-07-25Particles greater than 10 μm ≤ 6,000 in size44Particles greater than 25 μm ≤ 600 in size1Potency[^g^](#t1fn0007){ref-type="fn"}(NT-Ab titer (log~10~)/vial)MBP-JE vaccineNot lower than the neutralizing antibody titer of the standard2.77 (Reference: 2.76)[^3][^4][^5][^6][^7][^8][^9][^10]

This study was conducted over a-2 year period (approximately), which included manufacture and QC testing of the candidate material. During the 2^nd^ year, a collaborative study was performed to confirm the potency of the candidate material. Four institutions, including MFDS and Korean JE vaccine manufacturers; Boryung Biopharma, Co., Green Cross, Corp., and Korea Vaccine, Co., participated in this collaborative study. As shown in [Table 2](#t0002){ref-type="table"}, each of the institutions, randomly designated A to D, performed 10 iterations of plaque reduction neutralization (PRN) assays to compare the potency of the 2^nd^ standard and the 3^rd^ standard candidate material. Plaque reduction neutralization assays currently used for lot release testing of inactivated JE vaccine products measure the extent of plaque reduction in chicken embryo cells previously inoculated with serum from mice immunized with vaccine products or national standard, followed by exposure to a suspension of challenge virus.[@cit0006] The mean values of potency were 2.67 and 2.69 neutralizing-antibody (NT-Ab) titers (log~10~) for the 2^nd^ and 3^rd^ standard materials, respectively, while the intra-assay coefficient of variation (CV) values for the various institutions were 6.69 and 7.92 for the 2^nd^ and 3^rd^ standard materials, respectively. The proficiency of the 4 test institutions in terms of Z-scores were −0.05, 0.19, −0.25, and −0.15 for the 2^nd^ national standard and 0.46, 0.60, −0.74, and −0.32 for the 3^rd^ national standard candidate material, for institutions A, B, C, and D, respectively. As all values were within the range of ± 2, the proficiency between the institutions was determined to be satisfactory. As shown in [Figure 1](#f0001){ref-type="fig"}, based on the results from the collaborative study between the 4 institutions, the assigned potency of the 3^rd^ national standard candidate material was determined to be 2.69 NT-Ab titer (log~10~) per vial. The upper and lower limits of the 95% confidence interval of the mean were 2.76 and 2.62 for the 3^rd^ standard candidate material and 2.72 and 2.61 for the 2^nd^ standard material. Additionally, as the *p*-value was 0.53 (which exceeded 0.05) it was concluded that there was no significant difference between the 2^nd^ national standard and the 3^rd^ standard candidate material. Figure 1.The assigned potency of the 3^rd^ national JE vaccine standard candidate material The potency of the candidate material was determined to be 2.69 NT-Ab titer (log~10~) via statistical analysis of results of 40 PRN assays performed by 4 institutions. Geometric mean titers ± SDs were 2.67 ± 0.18 and 2.69 ± 0.21 for the 2^nd^ and the 3^rd^ standard material, respectively. Table 2.Results of the collaborative study comparing the potency of the JE vaccine standard material.  ResultStandard MaterialLaboratory^a^N[^b^](#t2fn0002){ref-type="fn"}GMT[^c^](#t2fn0003){ref-type="fn"}GCV[^d^](#t2fn0004){ref-type="fn"}(%)Inter GCV[^e^](#t2fn0005){ref-type="fn"}(%)2^nd^(code no. 07/022)A102.805.976.69B102.821.72C102.483.45D102.561.733^rd^ (candidate)A102.906.527.92B102.852.20C102.471.49D102.552.20[^11][^12][^13][^14][^15]

QC tests of the 3^rd^ national standard candidate material for the Nakayama-NIH strain-based JE vaccine revealed that the candidate material fulfilled the criteria described by the current official compendium of Korea. The collaborative study found that the potency of the 3^rd^ national standard material (2.69 NT-Ab titer (log~10~) per vial) was equivalent to that of the 2^nd^ national standard. Therefore, the tested candidate material was established as the national standard for potency testing of the JE vaccine following the 2^nd^ national standard in Korea. However, there is a recent, active, international movement to transition from *in vivo* potency testing to more sensitive and reproducible *in vitro* tests.[@cit0008] Accordingly, the application of *in vitro* methods for lot release testing will require additional studies to estimate the *in vitro* potency values for the newly established 3^rd^ national JE vaccine standard.
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[^1]: Color versions of one or more figures in this article can be found online at [www.tandfonline.com/khvi](http://www.tandfonline.com/khvi).
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[^3]: *Notes.* All assays, except potency tests, were performed according to the general testing protocols of Korean Pharmacopoeia (KP-07). The potency test was performed according to the method for JE vaccine as described in the Minimum Requirements for Biological Products (MBP-JE vaccine). In detail, 4-week-old Institute for Cancer Research (ICR) mice were administered with the diluted solution for the test sample and standard material via intraperitoneal injection twice in a 7-day interval. Next, serum samples were collected from the mice 7 days after the 2nd injection and incubated for 90 min at 36 ± 1°C with a suspension consisting of challenge virus (JEV-Nakayama-NIH strain; 200 PFUs/0.4 mL). Subsequently, the mixed solutions were transferred to plates containing cultured chicken embryo cells and allowed to react for 90 min. The cells were then stratified and cultured for 2 days in a CO~2~ incubator. The plaque reduction rate was calculated for the experimental group as well as the control group (treated with culture medium alone), and the neutralizing capacities of the antibodies of each serum were determined.

[^4]: Protein content: Determined by quantification of ammonia, the byproduct of distillation after decomposing the protein (precipitated by trichloroacetic acid) using sulfuric acid

[^5]: pH: Measured using the potentiometric instrument (pH meter) at 25 ± 2°C

[^6]: Moisture content: Frozen weight of test specimens that were vacuum-dried at 60°C for 3 hours

[^7]: Sterility: Determined by monitoring of bacterial or fungal growth for 14 days under both aerobic (at 20--25°C) and anaerobic (at 30--35°C) conditions

[^8]: Foreign insoluble matter: Manually observed and counted (at 3,200 Lux) with the specimen suspended in solvent

[^9]: Insoluble particulate matter for injection: Measured using a particle counter, with the specimen dissolved in de-ionized water

[^10]: Potency: Result of PRN assay using the 2^nd^ national standard as a reference material (shown in parentheses) in the test procedure.

[^11]: *Notes.* ^a^Laboratory: one of the participating laboratories, the National Center for Lot Release of the MFDS, Green Cross Corp. (Korea), Boryung Biopharma. Co. (Korea), and Korea Vaccine Co. (Korea) (in randomized order)

[^12]: N: number of tests

[^13]: GMT: geometric mean titer. GMT was calculated by dividing the sum of the test results by the test number (10) for each testing institution

[^14]: GCV: geometric coefficient of variation among tests for each test institution. GCV was calculated by dividing the standard deviation of the test results (SD of A, B, C, D = 0.17, 0.05, 0.09, 0.04 for the 2^nd^ standard, respectively, and 0.19, 0.06, 0.04, 0.06 for the 3^rd^ standard candidate, respectively) by the GMT for each testing institution

[^15]: Inter GCV: geometric coefficient of variation between the test institutions for each standard material. Inter GCV was calculated by dividing the standard deviation of the total test results (SD of 40 tests = 0.18 for 2^nd^ standard and 0.21 for 3^rd^ standard candidate) by GMT (GMT of 40 tests = 2.66 for 2^nd^ standard and 2.68 for 3^rd^ standard candidate) for each standard material.
